Compare
Advanced Biomed Inc. vs Aclarion, Inc. vs Renalytix plc vs CapForce Inc.
| Latest fiscal year | Advanced Biomed Inc. ADVBRevenue covers only part of its income (partial revenue) | Aclarion, Inc. ACON | Renalytix plc RNLXYLast annual report: year ended 2024-06-30 | CapForce Inc. CFOR |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2024-06-30 | 2025-12-31 |
| Revenue | n/a | $75.7K | $2.29M | $30.20M |
| Revenue growth (YoY) | n/a | +65.6% | -32.7% | +481.2% |
| Gross margin | n/a | 9.0% | 6.8% | n/a |
| Operating margin | n/a | n/m | n/m | 79.6% |
| Net margin | n/a | n/m | n/m | 78.2% |
| Net income | $6.68M | -$7.23M | -$33.46M | $23.62M |
| EPS (Diluted) | $5.33 | -$13.61 | -$0.31 | $2.32 |
| Operating cash flow | -$1.95M | -$7.16M | -$30.11M | -$1.18M |
| Free cash flow | n/a | -$7.19M | n/a | -$1.23M |
| Cash & equivalents | n/a | $12.02M | $4.68M | $531.3K |
| Total assets | $13.75M | $13.67M | $7.97M | $38.06M |
| Total liabilities | $1.47M | $837.3K | $15.83M | $6.20M |
| Shareholders' equity | $12.28M | $12.84M | -$7.85M | $31.86M |
| Return on year-end equity | 54.4% | -56.4% | n/a | 74.1% |
| Shares outstanding | 1.65M | 854.4K | 154.37M | 10.15M |
Revenue, most recent five fiscal years
| Fiscal year | Advanced Biomed Inc. | Aclarion, Inc. | Renalytix plc | CapForce Inc. |
|---|---|---|---|---|
| Latest | n/a | $75.7K Ended 2025-12-31 | $2.29M Ended 2024-06-30 | $30.20M Ended 2025-12-31 |
| 1 year earlier | n/a | $45.7K Ended 2024-12-31 | $3.40M Ended 2023-06-30 | $5.20M Ended 2024-12-31 |
| 2 years earlier | n/a | $75.4K Ended 2023-12-31 | $2.97M Ended 2022-06-30 | $3.42M Ended 2023-12-31 |
| 3 years earlier | n/a | $60.4K Ended 2022-12-31 | $1.49M Ended 2021-06-30 | $2.61M Ended 2022-12-31 |
| 4 years earlier | n/a | $60.3K Ended 2021-12-31 | $0 Ended 2020-06-30 | $4.31M Ended 2021-12-31 |